Skip to main content
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
Pediatric low-grade gliomas: implications of the biologic era.
Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
Response to "Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of paediatric brain tumors".
Pediatric high-grade glioma: biologically and clinically in need of new thinking.
Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors.
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
RO-02CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH WORSE EXECUTIVE FUNCTION IN PEDIATRIC BRAIN TUMOR SURVIVORS.
Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas.
CBIO-31MECHANISMS OF RESISTANCE TO EGFR INHIBITION REVEAL METABOLIC VULNERABILITIES IN HUMAN GBM.